Hepatocellular Carcinoma News and Research RSS Feed - Hepatocellular Carcinoma News and Research

Researchers examine how terpenes can inhibit growth of liver cancer cells

Researchers examine how terpenes can inhibit growth of liver cancer cells

As main component of essential oils, terpenes can inhibit the growth of different cancer cells. Researchers from the Ruhr-University Bochum headed by Prof Dr Dr Dr Hanns Hatt have analysed this process in liver cancer cells in detail. [More]
GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). [More]
Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati Therapeutics, Inc. today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl. [More]
Study underscores the importance of appropriate testing, support and care for HCV patients

Study underscores the importance of appropriate testing, support and care for HCV patients

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. [More]
Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
New study highlights importance of generating awareness about HCV testing, support and care

New study highlights importance of generating awareness about HCV testing, support and care

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. This real-life' view of the HCV patient care continuum in a major U.S. urban area is published in Hepatology, a journal of the American Association for the Study of Liver Diseases, and highlights the importance of generating awareness among clinicians and at-risk groups about appropriate HCV testing, referral, support and care. [More]
Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. [More]
Oncologists examine efficacy of rose bengal against cancer

Oncologists examine efficacy of rose bengal against cancer

Rose Bengal has been around for decades starting as a way to dye wool. Originally used in medicine as a stain for ophthalmologists, it has a solid safety record going back to the 1930s. Recently, oncologists have examined its efficacy against cancer, specifically melanoma. [More]
Scientists review HBV-associated tumor microenvironment in hepatocellular carcinoma

Scientists review HBV-associated tumor microenvironment in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over recent years. Globally, there are approximately 750,000 new cases of liver cancer reported each year. Importantly, population-based studies show that HCC ranks as the third leading cause of cancer-related deaths worldwide. [More]
CARsgen announces completion of series A financing

CARsgen announces completion of series A financing

CARsgen, a leader in the development of Chimeric Antigen Receptors T (CAR-T) cell immunotherapy to treat a variety of cancers, today announced the completion of a series A financing led by BVCF, a China-based healthcare private equity fund. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
Unique immunochemotherapy approach to treating pancreatic cancer

Unique immunochemotherapy approach to treating pancreatic cancer

VCU Massey Cancer Center and VCU Institute of Molecular Medicine researchers discovered a unique approach to treating pancreatic cancer that may be potentially safe and effective. The treatment method involves immunochemotherapy - a combination of chemotherapy and immunotherapy, which uses the patient's own immune system to help fight against disease. [More]
Study examines overall survival of patients with chronic HCV infection, cirrhosis

Study examines overall survival of patients with chronic HCV infection, cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced survival, according to a study in the November 12 issue of JAMA. [More]
Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

Genoscience Pharma, a company focused on discovering and developing small molecules to treat cancer by targeting cancer stem cells, today announces that it will present data on its most promising candidate at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014. [More]
Researchers examine whether new drug offers added benefit for patients with chronic HCV

Researchers examine whether new drug offers added benefit for patients with chronic HCV

The drug simeprevir has been available since May 2014 for the treatment of adult patients with chronic hepatitis C infection. [More]
Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced successful completion of a Phase 1a clinical study of NVR-1221. [More]
Research findings call for clinical testing of relevant drugs to prevent NASH

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation. [More]

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech Inc. today announced its financial results and operational highlights for the second quarter ended June 30, 2014. [More]

Computer simulation forecasts favorable trends in eradicating hepatitis C

Effective new drugs and screening would make hepatitis C a rare disease by 2036, according to a computer simulation conducted by The University of Texas MD Anderson Cancer Center and the University of Pittsburgh Graduate School of Public Health. [More]

Hepatitis C could become a rare disease by 2036

Effective new drugs and screening would make hepatitis C a rare disease by 2036, according to a computer simulation conducted by The University of Texas MD Anderson Cancer Center and the University of Pittsburgh Graduate School of Public Health. The results of the simulation are reported in the August 5 edition of the journal Annals of Internal Medicine. [More]